StockData
PDS Biotechnology Corp logo

PDS Biotechnology Corp (PDSB) company profile

PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
$0.89−0.03 (-3.28%)

Close on Nov 17, 2026Market cap $50.03MP/E –Yield –

About PDS Biotechnology

Pharmaceutical Preparations, SIC 2834

PDS Biotechnology Corporation is a clinical-stage immunotherapy company that develops targeted cancer and infectious disease immunotherapies. The company designs investigational therapies utilizing its proprietary Versamune T-cell-activating platform, both alone and combined with PDS01ADC, an antibody-drug conjugate fused with interleukin 12. It also develops the Infectimune platform to produce preventive vaccines directed against infectious pathogens. These platforms are engineered to stimulate polyfunctional CD4 helper and CD8 killer T cells, as well as disease-specific neutralizing antibodies, to combat malignancies and infectious agents.

The company operates in the biotechnology and pharmaceutical sector. Its clinical pipeline includes candidates such as PDS0101 and PDS0103, which are evaluated in trials targeting indications including HPV16-positive head and neck squamous cell carcinoma, advanced cervical cancer, and colorectal cancer. PDS Biotechnology Corporation maintains its principal executive offices in Princeton, New Jersey.

Summary of the business section of PDS Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
PDS Biotechnology Corp
Headquarters
Princeton, NJ
Address
303a College Road East 08540
Phone
(800) 208-3343
Employees
21, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Short Hills, New Jersey

Stock & identifiers

Ticker
PDSB
Exchange
Nasdaq
IPO date
Oct 2, 2015
Shares outstanding
56M, Aug 6, 2026
Public float
$60.15M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, May 14, 2019; 1-for-20 reverse, Mar 18, 2019
SEC CIK
1472091
CUSIP
70465T107
ISIN
US70465T1079
FIGI
BBG004NCDK82
Share class FIGI
BBG004NCDKL7
LEI
5493002KU8ACFTSMC935
EIN
26-4231384

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Frank Bedu-AddoPresident/CEO, Director866,050
Biotechnology Corp PDSChief Scientific Officer–
Janetta TrochimiukPrincipal Accounting Officer1,124
Gregory ConnChief Scientific Officer115,545
Spencer D. BrownSenior VP, General Counsel–
Kirk V. ShepardChief Medical Officer–
Stephan ToutainChief Operating Officer–
Lars BoesgaardChief Financial Officer–
John Andrew DawsonDirector–
Deborah RamsdellDirector–
Bruce WendelDirector–
Patrick Soon-ShiongDirector–
Arnold James BanaagDirector–
Otis W. BrawleyDirector–
Kamil Ali-JacksonDirector11,764
Ilian IlievDirector–
Gregory Gene FreitagDirector61,213
Stephen C. GloverDirector78,851

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$828.31K$630.19K$675.47K$6–
FY2024$2.26M-$217.79K$1.13M$12–
FY2023$5.01M-$2.39M$1.81M$38–
FY2022$2.30M$5.45M$756.42K$163–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Frank Bedu-Addo, Ph.D.
Chief Executive Officer
$615.32K$193.50K$19.49K$828.31K-63%
Kirk Shepard, M.D.
Chief Medical Officer
$463.50K$193.50K$20.32K$677.32K-49%
Stephan Toutain
Chief Operating Officer
$463.50K$193.50K$16.63K$673.63K-28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 2, 2015
Offer price
$11.00
Securities offered
7,315,151
Gross proceeds
$80.47M
Exchange
Nasdaq
First trading day
Sep 30, 2015
First-day close
$11.000.0%
Lock-up ends (est.)
Mar 28, 2016

“The initial public offering price of our common stock is $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 21 employees, all of whom were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?